Floor

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Retrieved on: 
Monday, March 4, 2024

WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the closing of its previously announced underwritten public offering of 18,157,895 shares of common stock at a public offering price of $9.50 per share, which includes 2,368,421 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the closing of its previously announced underwritten public offering of 18,157,895 shares of common stock at a public offering price of $9.50 per share, which includes 2,368,421 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The total gross proceeds of the public offering were approximately $172.5 million, before deducting underwriting discounts and commissions and offering expenses payable by Arcutis.
  • All of the shares in the public offering were sold by Arcutis.
  • Morgan Stanley, TD Cowen, and Guggenheim Securities acted as joint lead bookrunning managers for the offering.

West Red Lake Gold Announces Upsize to Previously Announced Private Placement

Retrieved on: 
Friday, March 1, 2024

TORONTO, March 01, 2024 (GLOBE NEWSWIRE) -- West Red Lake Gold Mines Ltd. (“West Red Lake Gold” or “WRLG” or the “Company”) (TSXV: WRLG) (OTCQB: WRLGF), is pleased to announce that, due to strong demand, it has agreed with Raymond James Ltd. as lead agent, on behalf of a syndicate of agents (collectively, the “Agents”), to increase the size of its previously announced private placement of units (the “Units”) to US$23,000,000 (the “Offering”) from US$20,000,000. The Agents will have the option to sell up to an additional 15% of the Units offered, exercisable, in whole or in part, at any time up to 48 hours prior to the Closing Date (as defined below) to cover over-allotments, if any.

Key Points: 
  • TORONTO, March 01, 2024 (GLOBE NEWSWIRE) -- West Red Lake Gold Mines Ltd. (“West Red Lake Gold” or “WRLG” or the “Company”) (TSXV: WRLG) (OTCQB: WRLGF), is pleased to announce that, due to strong demand, it has agreed with Raymond James Ltd. as lead agent, on behalf of a syndicate of agents (collectively, the “Agents”), to increase the size of its previously announced private placement of units (the “Units”) to US$23,000,000 (the “Offering”) from US$20,000,000.
  • Commencing January 1, 2026, the Company will cause gold to be placed in escrow on a quarterly basis into a gold trust account.
  • The Notes will amortize based on a guaranteed floor price of US$1,800 per ounce of gold (the “Floor Price”).
  • Any excess proceeds by which the gold price exceeds the Floor Price will be paid to investors as a premium.

Tarsus Announces Pricing of $100.0 Million Public Offering

Retrieved on: 
Friday, March 1, 2024

In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 468,750 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 468,750 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tarsus, are expected to be approximately $100.0 million, excluding any exercise of the underwriters’ option to purchase additional shares.
  • The offering is expected to close March 5, 2024, subject to the satisfaction of customary closing conditions.
  • Goldman Sachs & Co. LLC, BofA Securities, Guggenheim Securities, LLC and Oppenheimer & Co. are acting as joint book-running managers for the offering.

Tarsus Announces Proposed $100.0 Million Public Offering

Retrieved on: 
Thursday, February 29, 2024

Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering.

Key Points: 
  • Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering.
  • All securities in the proposed offering are to be sold by Tarsus.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Goldman Sachs & Co. LLC, BofA Securities, Guggenheim Securities, LLC and Oppenheimer & Co. are acting as joint book-running managers for the offering.

Arcutis Announces Pricing of $150 Million Public Offering

Retrieved on: 
Thursday, February 29, 2024

WESTLAKE VILLAGE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of common stock.

Key Points: 
  • WESTLAKE VILLAGE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of common stock.
  • The shares of common stock are being sold at a public offering price of $9.50 per share.
  • All shares of common stock to be sold in the offering are being offered by Arcutis.
  • The gross proceeds to Arcutis from the offering are expected to be approximately $150.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Arcutis and assuming no exercise of the underwriters’ option to purchase additional shares.

Arcutis Announces Proposed Public Offering

Retrieved on: 
Wednesday, February 28, 2024

All of the shares of common stock and pre-funded warrants in this offering are being sold by Arcutis.

Key Points: 
  • All of the shares of common stock and pre-funded warrants in this offering are being sold by Arcutis.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • In addition, Arcutis intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock at the public offering price per share.
  • Morgan Stanley, TD Cowen, and Guggenheim Securities are acting as joint lead bookrunning managers for the proposed offering.

West Red Lake Gold Announces a US$20 Million Private Placement of Gold Linked Notes

Retrieved on: 
Tuesday, February 27, 2024

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- West Red Lake Gold Mines Ltd. (“West Red Lake Gold” or “WRLG” or the “Company”) (TSXV: WRLG) (OTCQB: WRLGF), is pleased to announce that it has entered into an agreement with Raymond James Ltd. to act as sole bookrunner and lead agent, on behalf of a syndicate of agents (together, the “Agents”), in connection with a marketed “best efforts” private placement of units of the Company (each, a “Unit”) at a price of US$1,000 per Unit (the “Offering Price”) for gross proceeds of US$20,000,000 (the “Offering”). The Agents will have the option to sell up to an additional 15% of the Units offered, exercisable, in whole or in part, at any time up to 48 hours prior to the Closing Date (as defined below) to cover over-allotments, if any.

Key Points: 
  • Each Unit will contain gold-linked notes in the aggregate principal amount of US$1,000 (the “Notes”) and 710 common share purchase warrants (the “Warrants”).
  • Commencing January 1, 2026, the Company will cause gold to be placed in escrow on a quarterly basis into a gold trust account.
  • The Notes will amortize based on a guaranteed floor price of US$1,800 per ounce of gold (the “Floor Price”).
  • Any excess proceeds by which the gold price exceeds the Floor Price will be paid to investors as a premium.

Kratos Defense & Security Solutions, Inc. Prices Public Offering of Common Stock

Retrieved on: 
Friday, February 23, 2024

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kratos Defense & Security Solutions, Inc. (“Kratos”) (NASDAQ: KTOS), a Technology Company in the Defense, National Security and Global Markets, today announced the pricing of an underwritten offering of 16,666,667 shares of its common stock at a public offering price of $18.00 per share pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the “SEC”).

Key Points: 
  • SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kratos Defense & Security Solutions, Inc. (“Kratos”) (NASDAQ: KTOS), a Technology Company in the Defense, National Security and Global Markets, today announced the pricing of an underwritten offering of 16,666,667 shares of its common stock at a public offering price of $18.00 per share pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the “SEC”).
  • The net proceeds to Kratos from the offering, after deducting underwriting discounts and commissions, are expected to be approximately $288 million.
  • Kratos has also granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of common stock.
  • All of the shares in the offering are to be sold by Kratos.

Kratos Defense & Security Solutions, Inc. Announces Proposed Public Offering of Common Stock

Retrieved on: 
Wednesday, February 21, 2024

The underwriters will have a 30-day option to purchase up to an additional $45,000,000 of shares of common stock from Kratos.

Key Points: 
  • The underwriters will have a 30-day option to purchase up to an additional $45,000,000 of shares of common stock from Kratos.
  • All of the shares in the offering are to be sold by Kratos.
  • The proposed offering is subject to market and other conditions.
  • The preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC.

Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants

Retrieved on: 
Friday, March 1, 2024

The warrants have an exercise price of $20.00 per share and are exercisable immediately and will expire five years following the date of issuance.

Key Points: 
  • The warrants have an exercise price of $20.00 per share and are exercisable immediately and will expire five years following the date of issuance.
  • The financing consisted of participation from leading life sciences investors, including Perceptive Advisors, Janus Henderson Investors, Aquilo Capital Management, LLC and LYFE Capital.
  • In addition, Precision BioSciences has granted the underwriter a 30-day option to purchase up to an additional 375,000 shares of its common stock and/or warrants to purchase up to 375,000 shares of common stock, at the combined public offering price and less underwriting discounts and commissions.
  • All shares of common stock and accompanying warrants to be sold in the offering will be sold by Precision.